Dernières nouvelles pour Pfizer (NYSE:PFE) Stock

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

ViiV Healthcare announced Wednesday the latest findings from its <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">EMBRACE phase 2b study</a>.
The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), kept viral levels suppressed in adults living with HIV who were already <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44280792/viiv-healthcares-investigational-broadly-neutralising-antibody-n6ls-successfully-maintains-viral-s" rel="noreferrer noopener">stable on treatment</a>.
These results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
Results from the EMBRACE study at the six-month primary endpoint showed:
<ul>
<li>96% of participants receiving VH109 60mg/kg intravenously (IV) and 88% receiving VH109 3000mg subcutaneously (SC) with rHuPH20 maintained HIV-1 RNA levels below 50 copies/mL, compared to 96% in the standard-of-care group.</li>
</ul>
<ul>
<li>Overall, 4% of the IV group and 6% of the SC group had HIV-1 RNA levels of 50 copies/mL or higher when measured at month six, compared to none in the standard-of-care group.</li>
</ul>
<ul>
<li>VH109 was generally well tolerated, though infusion site reactions were more frequent with SC administration, occurring in 14% compared to none with IV administration.</li>
</ul>
<ul>
<li>ViiV Healthcare will progress a six-month IV formulation of VH109 in combination with CAB LA for further evaluation in an EMBRACE part two trial.</li>
</ul>
The company also presented data from two phase 2a proof-of-concept studies of investigational antiretroviral therapies, VH4524184 <a href="https://www.benzinga.com/pressreleases/25/03/b44261960/viiv-healthcare-showcases-leadership-in-long-acting-injectables-innovation-at-croi-2025-with-data-" target="_blank" rel="noreferrer noopener">(VH184) and VH4011499 (VH499)</a>.
Also Read: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39915897/pfizer-and-gsks-viiv-healthcares-two-drug-hiv-treatment-matches-gileads-three-drug-combo-in-major" target="_blank" rel="noreferrer noopener">Pfizer And GSK&#8217;s ViiV Healthcare&#8217;s Two-Drug HIV Treatment Matches Gilead&#8217;s Three-Drug Combo In Major Trial</a></li>
</ul>
VH184 demonstrated potency at all doses. After 10 days of monotherapy, the average decreases were -1.17, -2.15, and -2.31 log10 copies/mL for the 10mg, 50mg, and 300mg doses, respectively.
<ul>
<li>The maximum viral load decline (-2.69 log10) was observed in the 300mg dose. Additionally, no drug-resistance mutations were observed at the end of the study.</li>
<li>Long-acting formulations of VH184 in adults without HIV are being evaluated in an ongoing phase 1 study.</li>
</ul>
<ul>
<li>The trial of VH499 showed that all oral doses (25mg, 100mg, and 250mg) led to a decrease in HIV-1 viral load ranging from -2.2 log10 copies/mL in the 250mg arm to -1.8 log10 copies/mL in the 25mg and 100mg arms. VH499 was well tolerated, with all adverse events being mild to moderate in severity.</li>
<li>There were no adverse events leading to withdrawal, and no serious adverse events were reported</li>
<li>On day 11, one individual on the 25mg dose developed a single mutation associated with reduced susceptibility to capsid inhibitors.</li>
</ul>
ViiV Healthcare is majority owned by GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), with Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Shionogi as shareholders.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44282015/cannabis-firm-cresco-labs-reports-mixed-q4-ceo-says-company-will-strategically-deploy-capital-to-create-growth-in-2025" target="_blank" rel="noreferrer noopener">Cannabis Firm Cresco Labs Reports Mixed Q4, CEO Says Company Will &#8216;Strategically Deploy Capital To Create Growth&#8217; In 2025</a></li>
</ul>

Biotech

Large Cap

News

Health Care

General

GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study

<a href="https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions" title="https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions">https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions</a>

Legal

'Telehealth Platforms In Senators' Crosshairs Over Relationship With Eli Lilly, Pfizer; In Letters, Lawmakers Question If Direct-To-Consumer Deals Could Influence Prescriptions' - STAT News

<ul>
<li>Results from the phase IIb study, EMBRACE, demonstrate that N6LS, a bNAb administered every four months, effectively maintained undetectable viral load when combined with cabotegravir long-acting (CAB LA)</li>
<li>Results add to the growing body of evidence that N6LS is a potent antiviral that can function as a component of a complete antiretroviral regimen</li>
<li>EMBRACE study to continue investigating a combination of N6LS dosed at six months with CAB LA</li>
</ul>
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company's EMBRACE phase IIb study.1 The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV who were already stable on treatment. It was also well tolerated by participants.
These results were presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, U.S.

ViiV Healthcare Announces Findings From The Company's EMBRACE Phase IIb Study; N6LS Maintains Viral Suppression In Long-acting Treatment Of HIV

Guggenheim analyst Vamil Divan reiterates Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) from Buy to Buy.

Reiteration

Analyst Ratings

Guggenheim Reiterates Buy on Pfizerto Buy

Investors with a lot of money to spend have taken a bullish stance on Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 40 uncommon options trades for Pfizer.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.
Out of all of the special options we uncovered, 18 are puts, for a total amount of $1,087,923, and 22 are calls, for a total amount of $1,067,940.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $18.0 to $30.0 for Pfizer over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer's substantial trades, within a strike price spectrum from $18.0 to $30.0 over the preceding 30 days.
<h3>Pfizer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741717873_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$0.45</td>
<td>$0.41</td>
<td>$0.44</td>
<td>$25.00</td>
<td>$267.2K</td>
<td>59.8K</td>
<td>6.2K</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$0.71</td>
<td>$0.67</td>
<td>$0.7</td>
<td>$24.00</td>
<td>$140.0K</td>
<td>5.7K</td>
<td>2.1K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.85</td>
<td>$2.82</td>
<td>$2.85</td>
<td>$24.00</td>
<td>$114.0K</td>
<td>5.1K</td>
<td>49</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.63</td>
<td>$1.49</td>
<td>$1.49</td>
<td>$25.00</td>
<td>$84.9K</td>
<td>26.4K</td>
<td>1.6K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.15</td>
<td>$2.1</td>
<td>$2.11</td>
<td>$24.00</td>
<td>$84.3K</td>
<td>1.7K</td>
<td>402</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Pfizer's Current Market Status</h3>
<ul>
<li>With a volume of 23,384,615, the price of PFE is down -0.19% at $26.59. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 50 days.</li>
</ul>
<h3>What The Experts Say On Pfizer</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $33.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $33.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Looking At Pfizer's Recent Unusual Options Activity

Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">metastatic breast cancer</a>.
The results of the trial, released Monday, included estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer patients whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy.
These are the first pivotal<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44242539/arvinas-and-pfizer-announce-positive-topline-results-from-phase-3-veritac-2-clinical-trial" rel="noreferrer noopener"> data for vepdegestrant</a>.
The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42421011/arvinas-pfizer-partner-cancer-cancer-drug-shows-63-clinical-benefit-rate-in-combo-therapy-trial-in-breast-cancer-patients" rel="noreferrer noopener">Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients</a>
The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population.
The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population.
Overall survival was not mature at the time of the analysis, with less than a quarter of the required number of events having occurred.
The trial will continue to assess overall survival as a key secondary endpoint.
In the trial, vepdegestrant was generally well tolerated.
Detailed results from VERITAC-2 will be submitted for presentation at a medical meeting later this year.
In February 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for vepdegestrant for monotherapy for adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.
Price Action: ARVN stock is down 52.4% at $8.35 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44249407/bristol-myers-squibb-scoops-up-its-blood-cancer-drug-partner-2seventy-bio-in-286-million-deal" target="_blank" rel="noreferrer noopener">Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal</a></li>
</ul>
Image: Shutterstock

Movers

Trading Ideas

ARVN

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

<ul>
<li>VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival.</li>
<li>Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefit in a Phase 3 trial</li>
</ul>

Arvinas And Pfizer Announced Topline Results From The Phase 3 VERITAC-2 Trial Of Vepdegestrant Monotherapy Versus Fulvestrant In Adults With Advanced Or Metastatic Breast Cancer, The Trial Met Its Primary Endpoint Demonstrating A Statistically Significant And Clinically Meaningful Improvement In Progression-free Survival

Elizabeth Warren (D-Mass.) raised concerns on Monday about Robert F. Kennedy Jr.&#8217;s dinners with pharmaceutical executives at Mar-a-Lago. Warren questioned the integrity of Kennedy&#8217;s promise to &#8220;clean up corruption&#8221; as the Secretary of Health and Human Services. She highlighted the need for transparency regarding any potential deals made during these &#8220;million-dollar&#8221; dinners.
What Happened: Warren&#8217;s post on X comes in response to Kennedy&#8217;s actions since his confirmation as the Secretary of Health and Human Services under President Donald Trump. Kennedy, known for his controversial stance on vaccines, was confirmed by the Senate with a narrow vote of 52 to 48. His appointment has been <a href="https://in.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">met with skepticism</a>, particularly from Democrats, who unanimously opposed his nomination.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">RFK Jr. said he&#39;d &quot;clean up corruption&quot; as HHS Secretary. So why&#39;d he have dinner with Big Pharma executives at Mar-a-Lago with Trump? The American people deserve to know what kind of deals might have been made at those &quot;million-dollar&quot; dinners. <a href="https://t.co/Xun7nZ7gjj">https://t.co/Xun7nZ7gjj</a>
&mdash; Elizabeth Warren (@SenWarren) <a href="https://twitter.com/SenWarren/status/1899241046128595453?ref_src=twsrc%5Etfw">March 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
On Monday, Warren, along with Sen. Bernie Sanders (I-Vt.) and Sen. Ron Wyden (D-Ore.), wrote a letter to Kennedy and expressed concern over his attendance at private dinners with Big Pharma executives at Mar-a-Lago. 
These events, where executives paid millions of dollars to attend, raise questions about Kennedy&#8217;s commitment to reducing corporate influence in government, according to the senators. They wrote that Kennedy had previously vowed to &#8220;clean up corruption&#8221; and &#8220;stop the revolving door between industry and government,&#8221; but his participation in these dinners seems to contradict these promises.
The senators are requesting detailed information about these meetings, including what was discussed and any commitments made. They emphasize the need for transparency to ensure Kennedy&#8217;s actions align with his promises to protect Americans from high drug prices and corporate influence.
Pfizer and the Department of Health and Human Services did not immediately respond to Benzinga&#8217;s request for comments.
See Also: <a href="https://www.benzinga.com/25/03/44212384/bill-ackman-clashes-with-david-sacks-over-ukraine-strategy-asks-if-us-should-let-russia-take-the-rest-of-eastern-europe">Bill Ackman Clashes With David Sacks Over Ukraine Strategy, Asks If US Should Let Russia &#8216;Take The Rest Of Eastern Europe&#8217;</a>
Why It Matters: The letter referred to a Wall Street Journal <a href="https://www.wsj.com/politics/policy/trump-mar-o-lago-corporate-dinners-healthcare-executives-a8f171b0">report</a> from February, which noted that Pharmaceutical executives were among the biggest donors to Trump's fundraising efforts before and after his election, attending exclusive Mar-a-Lago dinners to influence policy. Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla and others blamed high drug prices on insurance middlemen, a view Trump later echoed publicly. Trump hinted at possible tariffs on pharmaceuticals, while drugmakers sought favorable regulatory outcomes, with the industry's influence under his administration remaining uncertain.
Others that have attended Mar-a-Lago dinners include UnitedHealth's Andrew Witty, CVS's David Joyner and Cigna Group's David Cordani, according to that report.
Warren&#8217;s comments add to the ongoing scrutiny surrounding Kennedy&#8217;s role and his interactions with major industry players. Meanwhile, Kennedy was slated to <a href="https://www.benzinga.com/markets/equities/25/03/44209953/rfk-jr-takes-on-food-giants-calls-meeting-with-pepsico-and-general-mills">meet with executives</a> from major food companies, including PepsiCo and General Mills, on Monday
The <a href="https://in.benzinga.com/25/02/43900398/measles-cases-surge-5x-in-us-in-a-week-cdc-reports-outbreak-primarily-originating-from-a-texas-county">recent increase in measles cases</a>, reported by the CDC, underscores the importance of transparent health policies. Kennedy&#8217;s controversial stance on vaccines and his interactions with industry leaders are critical in shaping public trust. 
Photo by Sheila Fitzgerald on Shutterstock
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

Elizabeth Warren Raises Questions On Robert F Kennedy's Mar-A-Lago Dinners With Big Pharma: American People Deserve To Know About The Deals Made

BioNTech SE&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 38 cents</a>.
The COVID-19 vaccine maker reported sales of 1.19 billion euros, compared to 1.48 billion euros, beating <a href="https://www.benzinga.com/pressreleases/25/03/g44215377/biontech-announces-fourth-quarter-and-full-year-2024-financial-results-and-corporate-update" target="_blank" rel="noreferrer noopener">consensus of 1.09 billion</a>.
The revenue decrease was primarily driven by lower sales of the company&#8217;s COVID-19 vaccines due to reduced market demand.
In addition, write-downs by BioNTech&#8217;s collaboration partner Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) significantly reduced the company&#8217;s gross profit share which negatively influenced its revenues.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44148407/fda-places-clinical-hold-on-biontechs-early-phase-trial-for-rna-based-malaria-vaccine" rel="noreferrer noopener">FDA Places Clinical Hold On BioNTech&#8217;s Early-Phase Trial For RNA-Based Malaria Vaccine</a>
&#8220;From the very beginning, BioNTech&#8217;s vision has been to translate our science into survival and become an immunotherapy powerhouse. In 2024, we made significant progress towards our vision through important oncology pipeline advancements, including the initiation of global Phase 3 clinical trials for our anti-PD-L1/VEGF-A bispecific antibody candidate BNT327 and key data updates from our mRNA cancer immunotherapy programs,&#8221;&nbsp;said BioNTech CEO Ugur Sahin. &#8220;We expect 2025 to be a data-rich year with multiple important updates from our priority programs&#8230;&#8221;
The cost of sales&nbsp;was 243.5&nbsp;million euros, compared to 179.1&nbsp;million euros a year ago, driven by COVID-19 vaccine sales, inventory write-<a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">downs, and scrapping</a>.
Research and development&nbsp;expenses were 611.8&nbsp;million euros compared to 577.8&nbsp;million euros a year ago, mainly influenced by advancing clinical studies for the company&#8217;s late-stage oncology product candidates.
Guidance: BioNTech expects its 2025 revenues of 1.7 billion-2.2 billion euros compared to consensus of 2.57 billion euros and revenue phasing similar to 2024, primarily concentrated in the last three to four months, driving the full-year revenue figure.
BioNTech expects to continue to focus investments on R&amp;D and scaling the business for late-stage development and commercial readiness in oncology.
Price Action: BNTX stock is down 3.39% at $105.10 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44200654/europe-based-ucbs-bimzelx-data-reveals-sustained-skin-clearance-in-inflammatory-skin-disorders" target="_blank" rel="noreferrer noopener">Europe-Based UCB&#8217;s Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders</a></li>
</ul>
Image by Shutterstock

Earnings

Guidance

BNTX

Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations

Deep-pocketed investors have adopted a bullish approach towards Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 27 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to $1,146,717.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $32.0 for Pfizer during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Pfizer's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale activity within a strike price range from $20.0 to $32.0 in the last 30 days. 
<h3>Pfizer Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741377787_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/04/25</td>
<td>$0.25</td>
<td>$0.22</td>
<td>$0.23</td>
<td>$25.00</td>
<td>$576.0K</td>
<td>35.2K</td>
<td>24.6K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.46</td>
<td>$1.42</td>
<td>$1.42</td>
<td>$26.00</td>
<td>$142.1K</td>
<td>24.5K</td>
<td>1.2K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$7.5</td>
<td>$7.15</td>
<td>$7.3</td>
<td>$20.00</td>
<td>$109.5K</td>
<td>8.3K</td>
<td>15</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.15</td>
<td>$1.63</td>
<td>$1.8</td>
<td>$25.00</td>
<td>$90.0K</td>
<td>59.8K</td>
<td>513</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$0.24</td>
<td>$0.22</td>
<td>$0.23</td>
<td>$26.00</td>
<td>$79.3K</td>
<td>26.1K</td>
<td>7.0K</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
<h3>Where Is Pfizer Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 37,526,981, the PFE's price is up by 1.73%, now at $26.7. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 54 days.</li>
</ul>
<h3>What The Experts Say On Pfizer</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $33.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Guggenheim downgraded its action to Buy with a price target of $33. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Pfizer's Options: A Look at What the Big Money is Thinking

<ul>
<li>CDC study follows measles outbreak amid declining vaccination rates</li>
<li>Kennedy's mixed messages on vaccines raise concerns</li>
<li>Autism rise attributed to broader screening, not vaccines</li>
</ul>
March 7 - The U.S. Centers for Disease Control and Prevention is planning a large study into potential connections between vaccines and autism, two sources familiar with the matter told Reuters, despite extensive scientific research that has disproven or failed to find evidence of such links.
It is unclear whether U.S. Health Secretary Robert F. Kennedy Jr, who has long promoted <a href="reuters://REALTIME/verb=NewsStory/ric=nL2N3PH1HA">anti-vaccine views</a>, is involved in the planned CDC study or how it would be carried out. The CDC and the Department of Health and Human Services were not immediately available for comment.
The CDC's move comes amid one of the largest <a href="reuters://REALTIME/verb=NewsStory/ric=nL3N3PN1WV">measles outbreaks</a> the U.S. has seen in the past decade, with more than 150 cases and two deaths in Texas and New Mexico. The outbreak has been fueled by declining vaccination rates in parts of the United States where parents have been falsely persuaded that such shots do more harm than good.
Kennedy, whose role includes authority over the CDC, has long sowed doubt over the safety of the combined vaccine for measles, mumps and rubella (MMR). In a cabinet meeting last week, Kennedy initially downplayed news that a school-aged child had died of measles in Texas, the first such death in a decade, calling such outbreaks ordinary and failing to mention the role of vaccination to prevent measles.
Over the weekend, Kennedy published an opinion piece on Fox News that promoted the role of vaccination, but also told parents vaccination was a personal choice and urged them to consult with their physician.
Kennedy did not immediately respond to a request for comment.
Autism diagnoses in the United States have increased significantly since 2000, intensifying public concern.
Many researchers attribute the <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3NJ17A">rise in diagnoses</a> to more widespread screening and the inclusion of a broader range of behaviors to describe the condition. But some public figures have popularized the idea that vaccines are to blame, an idea stemming from a since-debunked study from British researcher Andrew Wakefield in the late 1990s that connected a rise in autism diagnoses with widespread use of the MMR shot.
The causes of autism are unclear. No rigorous studies have found links between autism and vaccines or medications, or their components such as thimerosal or formaldehyde.
There is widespread speculation among scientists that its neurological characteristics may develop in utero, when the fetal brain is being wired. Studies have linked autism to maternal factors in pregnancy, and some research suggests a link to birth complications and timing.
President Donald Trump, in an address to Congress this week, cited the rise in autism among children. "So, we're going to find out what it is, and there's nobody better than Bobby and all of the people that are working with you," Trump said, referring to Kennedy.
Kennedy's anti-vaccine views have drawn concern among some Republicans. During Kennedy's confirmation hearing Senator Bill Cassidy, a Louisiana Republican and physician, suggested that the nominee disavow any links between vaccines and autism.
Kennedy denied that he was anti-vaccine, but did not acknowledge that such a link had been debunked.
This week Cassidy questioned Trump's nominee to lead the National Institutes of Health, Dr. Jay Bhattacharya, over his stance on investigating a potential link between autism and childhood vaccinations.
"I don't generally believe there is a link, based on my reading of the literature," Bhattacharya said. "But we do have a sharp rise in autism rates, and I don't think any scientist really knows the cause of it. I would support a broad scientific agenda based on data to get an answer to that."

MRNA

'U.S. CDC Plans Large Study Into Potential Connections Between Vaccines And Autism, Sources Say' - Reuters News

JEPI

PAYX

CNBC Halftime Report Final Trades: Paychex, Pfizer, JPMorgan Equity Premium Income ETF

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that Quebec has become the first province to publicly reimburse APRETUDE (cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.1
ViiV Healthcare commends the Quebec government for its decision to grant timely access to APRETUDE for at-risk individuals who could benefit from PrEP. APRETUDE is now listed under the Régie de L'assurance Maladie du Québec (RAMQ). With cases of HIV continuing to rise across Canada, including in Quebec where cases have increased 37 per cent between 2019 and 2022,2 this decision will have a meaningful impact on HIV prevention efforts in the province.
APRETUDE is the first and only long-acting injectable approved in Canada to help reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents aged 12 years and older, and weighing at least 35kg.1 Findings from two real-world evidence studies (OPERA and Trio Health cohorts) showed more than 99 per cent effectiveness of APRETUDE for PrEP in nearly 1,300 individuals.3,4&nbsp;APRETUDE for PrEP has demonstrated superior efficacy to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF tablets) in reducing the risk of HIV acquisition in two clinical trials, providing more options for PrEP for Canadians.1

Global

ViiV Healthcare Announces That Quebec Has Become The First Province To Publicly Reimburse  APRETUDE For Pre-Exposure Prophylaxis To Reduce The Risk Of Sexually Acquired HIV-1 Infection In At-Risk Individuals Who Are HIV-1 Negative

German Court Rules In Favor Of Moderna In Patent Lawsuit Against BioNTech And Pfizer; German Court Rules Pfizer, BioNTech Violated Moderna's Covid-19 Vaccine Patents

In light of potential tariff threats from President Donald Trump, Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla has suggested the possibility of shifting the company&#8217;s overseas manufacturing to its U.S. facilities.
What Happened: At the TD Cowen healthcare conference, Bourla indicated that Pfizer, which already boasts an extensive U.S. manufacturing network, could relocate production to its domestic plants to avoid any potential tariffs, reported Reuters on Monday.
His remarks come as the pharmaceutical industry braces for a possible 25% tariff on imported goods. &#8220;We&nbsp;have the capabilities here (in&nbsp;the U.S.) and the manufacturing&nbsp;sites are operating in good&nbsp;capacity right now. If something&nbsp;happens, we will try to&nbsp;mitigate it by transferring from&nbsp;manufacturing sites outside to the&nbsp;manufacturing sites here,&#8221; Bourla said.
Pfizer has 10 manufacturing facilities and two distribution centers in the United States. 
SEE ALSO:<a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets"> </a><a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets">Trump&#8217;s Tariffs Threaten Canada, Mexico, China — And American Wallets</a>
Why It Matters: This development follows a&nbsp;<a href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs">warning</a>&nbsp;from Trump to pharmaceutical companies in February. During a confidential meeting, the President urged drug companies to expedite the transfer of their overseas production to the U.S. or face the possibility of tariffs.
Among the attendees of this meeting were the CEOs of Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer, along with the head of the industry's largest lobbying group. The executives aimed to convince Trump to support measures targeting middlemen blamed for increasing out-of-pocket costs and to limit a law allowing the federal government to negotiate specific drug prices.
Though the Trump administration has hinted at possible exemptions to reciprocal tariffs for certain sectors, including pharmaceuticals, a final decision is yet to be made.
While many see reshoring as a potential solution to avoid tariffs, it may not be pragmatic. Independent healthcare analyst Joshua P. Cohen wrote in Forbes, &#8220;..this takes time and is logistically complex.&#8221; He stated that generic products might call for volume purchase guarantees, and a public-private partnership may be required to boost infrastructure and regulatory compliance. &#8220;Whether the Trump administration is prepared to co-invest in a long-term strategy remains to be seen,&#8221; says Cohen.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/general/social-media/25/03/44100560/reddit-co-founder-alexis-ohanian-joins-frank-mccourts-tiktok-bid-amid-competition-from-mrbeast-jesse-tinsley-and-reid-rasner">Reddit Co-Founder Alexis Ohanian Joins Frank McCourt&#8217;s TikTok Bid Amid Competition From MrBeast, Jesse Tinsley, And Reid Rasner</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst

Macro Economic Events

Economics

Pfizer Exec Says If There Are Significant Tariffs, Co Will Try To Move Outside Manufacturing To The U.S.

Kim Vaccarella bet her kids&#8217; college fund on her business and lost it all.
The founder of Bogg Bag dumped $60,000 into what she thought would be her big break in 2012—a massive order of her waterproof tote bags. When the shipment arrived, her heart sank. Black streaks covered every bag, rendering them unsellable.
&#8220;I went for broke and spent my kids&#8217; college money and bought a full container&#8217;s worth, and they were all bad,&#8221; Vaccarella <a href="https://www.cnbc.com/2025/02/22/highly-successful-ceos-share-best-tips-for-responding-to-setbacks.html">told CNBC Make It</a>.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 Billion Startup Investment Boom: How This Company's Explosive Growth Is Opening Doors For Everyday Investors With A New $500 Minimum</a></li>
</ul>
Instead of giving up, she donated the defective bags to Hurricane Sandy victims. Those recipients started asking where they could buy more. With renewed confidence, she secured a $120,000 loan from a family friend and rebuilt.&nbsp;
Today, Bogg Bag rakes in roughly $100 million annually.
Entrepreneurs <a href="https://www.benzinga.com/startups/24/12/42618228/mark-cuban-admits-ive-gotten-beat-after-losing-20-million-on-shark-tank-startups">face setbacks all the time</a>. Some crumble. Others transform those disasters into stepping stones. CNBC Make It interviewed a few business owners who survived potentially career-ending failures before building multimillion-dollar companies.
Karen Robinovitz and Sara Schiller launched The Sloomoo Institute, a hands-on slime experience venue, in October 2019. After investing $600,000, they sold $1 million in tickets their first week. Then COVID hit.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Five months after opening, they laid off 90 part-time workers, keeping just their co-CEOs, a bookkeeper, and their slime expert.
Rather than folding, they hustled. They switched to online slime sales. They created virtual slime-making camps for kids stuck at home. They ran corporate workshops for companies like Google and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) until they could fully reopen in 2021.
It paid off. Now, their five U.S. locations bring in about $4.3 million monthly from in-person tickets.
&#8220;We want people to know that you can choose to try, get out there and do something that&#8217;s never been done before,&#8221; Schiller told CNBC. &#8220;After what we&#8217;ve both been through, what are we going to be afraid of now?&#8221;
See Also: <a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a>
Sometimes the biggest obstacle is the reflection in the mirror. Shizu Okusa learned the lesson after watching her first company, Jrink, collapse despite seven years in business.
The cold-pressed juice company couldn&#8217;t overcome high costs and rapid spoilage. But Okusa admits her management style was the deeper problem.
&#8220;One of the key lessons was getting out of my own way,&#8221; Okusa told CNBC. She treated Jrink like her baby, refusing to trust her team with critical decisions. &#8220;In terms of allowing and hiring people that were much better than I was in certain areas of business. Now, I just move aside. I have my strengths and give my weaknesses away.&#8221;
These entrepreneurs&#8217; stories reveal common threads—an unwavering belief in your concept, willingness to adapt when plans implode, and knowing when to get out of your own way.
Read Next:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/arrived-private-credit-fund">Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom</a></li>
</ul>

From Losing $60K To Running a $100M Business: CEOs Share Their Biggest Lessons

On Tuesday, LAVA Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) initiated a process to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43936254/lava-announces-evaluation-of-strategic-options" rel="noreferrer noopener">review strategic options</a>.
The company implemented cost curtailment, including a workforce reduction, and has retained a financial advisor to support the strategic evaluation process.
LAVA Therapeutics will continue to enroll in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42912100/lava-doses-first-patient-in-phase-1-lava-1266-study-in-hematological-cancers" rel="noreferrer noopener">Phase 1 clinical study</a> evaluating the safety and pharmacokinetics of LAVA-1266 in hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and support its partnerships with Pfizer Inc and Johnson and Johnson.
In 2020, Lava Therapeutics <a target="_blank" href="https://www.lavatherapeutics.com/press-release/lava-therapeutics-announces-collaboration-with-janssen-to-develop-bi-specific-gamma-delta-t-cell-engager-therapeutics/" rel="noreferrer noopener">announced</a> a research and license agreement with Janssen Biotech, Inc. to discover and develop novel bispecific antibodies to gamma-delta T cells for cancer.
In March 2024, LAVA Therapeutics announced that Pfizer achieved a development milestone for PF-08046052 (formerly SGN-EGFRd2 /LAVA-1223), prompting the first milestone payment <a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37478540/lava-announces-clinical-development-milestone-achieved-by-pfizer-for-pf-08046052-formerly-sgn-egfr" rel="noreferrer noopener">of $7 million to LAVA</a>.
LAVA granted Seagen (acquired by Pfizer in December 2023) a worldwide exclusive license to PF-08046052 <a target="_blank" href="https://www.benzinga.com/pressreleases/22/09/b29006441/seagen-and-lava-therapeutics-announce-exclusive-worldwide-license-agreement-to-advance-lava-1223-a" rel="noreferrer noopener">in September 2022</a>.
As of December 31, 2024, the company&#8217;s cash balance was $76.6 million.
In December, the company&#8217;s said cash runway extended into 2027, based on a cash balance of $78.9 million as of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42410106/lava-reports-third-quarter-2024-financial-results-and-announces-pipeline-reprioritization-and-cash" rel="noreferrer noopener">September 30, 2024</a>.
On Thursday, HC Wainwright downgraded LAVA Therapeutics to Neutral from Buy with a <a target="_blank" href="https://www.benzinga.com/quote/LVTX/analyst-ratings" rel="noreferrer noopener">price target of $1.50</a>, citing pipeline overhang despite substantial cash reserve.
Analyst Arthur He writes, &#8220;While we are not surprised by management&#8217;s decision given the challenging market conditions, it does generate uncertainties regarding the company&#8217;s only clinical asset, LAVA-1266 for hematological malignancies, as it depends on the outcome of the strategic review.&#8221;
HC Wainwright expects three possible outcomes for LAVA Therapeutics in the next year:
<ul>
<li>Acquiring one or more proven drug candidates</li>
<li>Merging with another company through a reverse merger</li>
<li>Continuing its current operations while waiting for initial clinical results from LAVA-1266</li>
</ul>
LAVA-1266 could be sidelined in favor of new projects in the first two scenarios. Given this uncertainty, HC Wainwright believes it is best to wait for more clarity.
Price Action: LVTX stock is down 0.78% at $1.28 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/44046417/ani-pharmaceuticals-expects-strong-start-to-2025-on-back-of-cortrophin-gel-and-generics-lifts-annual-forecast" target="_blank" rel="noreferrer noopener">ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Downgrades

Price Target

LVTX

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

AMGN

VKTX

Drug Compounders Sue U.S. Drug Regulator Over Removal Of Novo Nordisk Diabetes, Weight Loss Drugs From Shortage List

https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-names-former-fda-director-patrizia-cavazzoni-chief-medical-officer-2025-02-24/#:~:text=Feb%2024%20(Reuters)%20%2D%20Pfizer,other%20medical%20functions%20at%20Pfizer

Management

'Pfizer Names Former FDA Director Patrizia Cavazzoni As Chief Medical Officer' - Reuters News

Press Releases

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate

Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

Quebec becomes first province to publicly reimburse APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP)

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1

ViiV Healthcare's investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV

ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP

AKYA

CMBM

CSCO

DOMO

FTSW

ICLR

ILMN

PRAH

QTRX

SFSF

SMMT

YDLE

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Pfizer

Actualités

Dernières nouvelles pour Pfizer (NYSE:PFE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL